Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells $34,601.64 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 4,727 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $34,601.64. Following the sale, the general counsel now owns 135,528 shares in the company, valued at approximately $992,064.96. This trade represents a 3.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Sera Prognostics Trading Down 7.6 %

Shares of Sera Prognostics stock opened at $6.44 on Friday. Sera Prognostics, Inc. has a 1 year low of $1.67 and a 1 year high of $12.35. The company has a 50-day moving average of $7.38 and a 200 day moving average of $7.64.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.09 million. During the same period last year, the firm earned ($0.23) EPS. Equities research analysts forecast that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Sera Prognostics

Several hedge funds have recently added to or reduced their stakes in SERA. Quest Partners LLC raised its position in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in Sera Prognostics during the 2nd quarter valued at about $68,000. SG Americas Securities LLC purchased a new position in Sera Prognostics in the third quarter worth about $78,000. Prime Capital Investment Advisors LLC purchased a new stake in shares of Sera Prognostics during the third quarter valued at approximately $104,000. Finally, MetLife Investment Management LLC grew its holdings in shares of Sera Prognostics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock valued at $135,000 after buying an additional 9,722 shares during the last quarter. 54.64% of the stock is owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.